摘要
Abstract
Objective To investigate the clinical efficacy and safety of low dose roxithromycin combined with doxofylline in patients with stable bronchiectasis. Method 88 patients with stable bronchiectasis in our hospital from November 2014 to June 2015 were randomly divided into observation group and control group, 44 cases in each group. The patients in observation group were given low dose roxithromycin combined with doxofylline therapy and the patients in control group were given low dose roxithromycin. The 24-hour sputum volume, times of acute exacerbation, lung function, clinical efficacy and adverse reactions of the two groups were observed and compared. Result During the 6-month treatment, the average times of acute exacerbation in observation group was significantly less than control group (P<0.05). After treatment, the 24-hour sputum volume in both observation group and control group had significantly reduced (P < 0.05), and the 24-hour sputum volume in observation group were significantly less than control group (P < 0.05). Two groups of patients with first second forced expiratory volume (FEV1), forced vital capacity (FVC) and expiratory flow peak (PEF) were significantly better than before treatment (P < 0.05), observation group of patients with FEV1, FVC and PEF were significantly better than control group (P<0.05). The total clinical effective rate in observation group was significantly higher than that of control group (χ2=4.064, P<0.05). The incidence of adverse drug reactions between observation group and control group showed no significant difference (P>0.05). Conclusion Low dose roxithromycin combined with doxofylline can significantly reduce the levels of 24-hour sputum volume and times of acute exacerbations of patients with stable bronchiectasis, with additional benefits of improving lung function, good overall effect and low rate of adverse reactions, which is worthy of clinical application.关键词
支气管扩张症/罗红霉素/多索茶碱Key words
Bronchiectasis/Roxithromycin/Doxofylline
